Chiesi Group, a global biopharmaceutical company headquartered in Parma, Italy, has announced a major investment in Nerviano (Milan, Italy), with the construction of a new facility for the production ...

Q4 2024 Earnings Call Transcript March 17, 2025 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $0.09, expectations were $0.07. Operator: Good morning, ladies and gentlemen ...

Chiesi along the years will grow ... And also if you could provide us with some framework, some frame of reference regarding the size of the market opportunity in NETs that you previously ...

By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company ...

The deals were instrumental for Chiesi to become a global company with expansion to several new countries including Canada, Australia and China, enter and grow its presence in the US market ...

By then, the pandemic was upon us and the treatment landscape had moved on anyway ... Luckily, Pharmaxis was partnered with ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns. Click to read why VRNA is a Hold.

Your donation allows us to keep sending journalists to speak ... such as Nestlé-owned Nespresso, the pharmaceutical Chiesi Group which is part of an industry heavily contributing to greenhouse ...

How Susan Kelechi Watson, who played Beth Pearson on 'This Is Us', did a callback to the hit NBC series on her new show, ...

A Phase II study for PRX-115 is now planned for 2H:25. 2024 product revenues rose 31%, driven by inventory builds of Elfabrio by Chiesi. 2024 revenues essentially matched our estimates at $53.4 ...